Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus BACTOCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus BACTOCILL.
AMPICILLIN TRIHYDRATE vs BACTOCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic